on partnership prospects.
In the CC, Dr. Cooper alluded, for the umpteenth time since 2016, that from SNO and JPM, there is interest in Ziopharm's platforms. I am personally liking the catbird-seat posture of the company on IL-12 partnerships that was expressed by Sath in the recent 4Q call:
>> So I think what I can say is that our cash runway conservatively does not assume any partnership and push at this point. So whatever we want to do with the program and progress it in our GBM and potentially other indications, we have assumed that the funding for that today comes from the Company for planning purposes and we lay out of the cash to runway. Obviously, when data rollout and we decide whether and which partnerships to explore that number could change. But conservatively, we have not built in any partnership funding in any of our analyses. <<
When purchasing a car, never fall in love with a vehicle. Be armed and ready to walk away and blow off the sales person. On your drive home in your old car, you will likely get a call to come back. After studying the price metrics, you gave them a fair offer which should satisfy both parties. Far more times than not, they come around to your terms. Good that the Research House is gaining Business Smarts.